ICD-10-PCS › X
ICD-10-PCS codes starting with X
734 codes, page 5 of 8. Every code ever valid for billing is listed, including those now retired.
| Code | Description | Status |
|---|---|---|
| XRHB3FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into Lumbar Vertebral Joint, Percutaneous Approach, New Technology Group 10 | Valid |
| XRHB4FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into Lumbar Vertebral Joint, Percutaneous Endoscopic Approach, New Technology Group 10 | Valid |
| XRHC0FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into 2 or more Lumbar Vertebral Joints, Open Approach, New Technology Group 10 | Valid |
| XRHC3FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into 2 or more Lumbar Vertebral Joints, Percutaneous Approach, New Technology Group 10 | Valid |
| XRHC4FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into 2 or more Lumbar Vertebral Joints, Percutaneous Endoscopic Approach, New Technology Group 10 | Valid |
| XRHD018 | Insertion of Posterior Spinal Motion Preservation Device into Lumbosacral Joint, Open Approach, New Technology Group 8 | Valid |
| XRHD0FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into Lumbosacral Joint, Open Approach, New Technology Group 10 | Valid |
| XRHD3FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into Lumbosacral Joint, Percutaneous Approach, New Technology Group 10 | Valid |
| XRHD4FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into Lumbosacral Joint, Percutaneous Endoscopic Approach, New Technology Group 10 | Valid |
| XRR | New Technology, Joints, Replacement | Not billable |
| XRRG0L8 | Replacement of Right Knee Joint with Synthetic Substitute, Lateral Meniscus, Open Approach, New Technology Group 8 | Valid |
| XRRG0M8 | Replacement of Right Knee Joint with Synthetic Substitute, Medial Meniscus, Open Approach, New Technology Group 8 | Valid |
| XRRH0L8 | Replacement of Left Knee Joint with Synthetic Substitute, Lateral Meniscus, Open Approach, New Technology Group 8 | Valid |
| XRRH0M8 | Replacement of Left Knee Joint with Synthetic Substitute, Medial Meniscus, Open Approach, New Technology Group 8 | Valid |
| XT2 | New Technology, Urinary System, Monitoring | Not billable |
| XT25XE5 | Monitoring of Kidney using Fluorescent Pyrazine, External Approach, New Technology Group 5 | Valid |
| XU7 | New Technology, Female Reproductive System, Dilation | Not billable |
| XU7G71B | Dilation of Vagina with Temporary Electromechanical Intraluminal Device, Via Natural or Artificial Opening, New Technology Group 11 | Valid |
| XV5 | New Technology, Male Reproductive System, Destruction through FY2023 | Retired |
| XV508A4 | Destruction of Prostate using Robotic Waterjet Ablation, Via Natural or Artificial Opening Endoscopic, New Technology Group 4 through FY2023 | Retired |
| XW0 | New Technology, Anatomical Regions, Introduction | Not billable |
| XW00X27 | Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7 through FY2026 | Retired |
| XW01318 | Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 | Valid |
| XW01329 | Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 | Valid |
| XW01348 | Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 | Valid |
| XW0134C | Introduction of Elamipretide into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 12 | Valid |
| XW0136A | Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10 | Valid |
| XW01397 | Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 through FY2026 | Retired |
| XW013F5 | Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 | Valid |
| XW013G6 | Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | Valid |
| XW013H6 | Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | Valid |
| XW013K6 | Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | Valid |
| XW013L9 | Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 | Valid |
| XW013S6 | Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | Valid |
| XW013S9 | Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 | Valid |
| XW013T6 | Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | Valid |
| XW013TB | Introduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11 | Valid |
| XW013U6 | Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | Valid |
| XW013V7 | Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 | Valid |
| XW013W5 | Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 | Valid |
| XW013W7 | Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 | Valid |
| XW01X27 | Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7 through FY2026 | Retired |
| XW020D8 | Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8 | Valid |
| XW023S6 | Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6 | Valid |
| XW023T6 | Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6 | Valid |
| XW023U6 | Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6 | Valid |
| XW023V7 | Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7 | Valid |
| XW023W7 | Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7 | Valid |
| XW023X7 | Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7 through FY2026 | Retired |
| XW023Y7 | Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7 | Valid |
| XW03306 | Introduction of Brexanolone into Peripheral Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW03308 | Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW0330B | Introduction of Alpha1-proteinase Inhibitor into Peripheral Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW0331B | Introduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW03321 | Introduction of Ceftazidime-Avibactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 1 through FY2021 | Retired |
| XW03326 | Introduction of Nerinitide into Peripheral Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW03331 | Introduction of Idarucizumab, Dabigatran Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 1 through FY2021 | Retired |
| XW03336 | Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW0333A | Introduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW03341 | Introduction of Isavuconazole Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 1 through FY2021 | Retired |
| XW0334A | Introduction of Cefepime-taniborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW03351 | Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1 through FY2021 | Retired |
| XW03357 | Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW03358 | Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW0335A | Introduction of Ceftobiprole Medocaril Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW03366 | Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW03367 | Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7 through FY2026 | Retired |
| XW03368 | Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW0336C | Introduction of Landiolol Antiarrhythmic into Peripheral Vein, Percutaneous Approach, New Technology Group 12 | Valid |
| XW03372 | Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2 | Valid |
| XW03377 | Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7 through FY2026 | Retired |
| XW03378 | Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW0337C | Introduction of Zimislecel Allogeneic Stem Cell-Derived Islet Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 12 | Valid |
| XW03387 | Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7 through FY2026 | Retired |
| XW03388 | Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW0338A | Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW03392 | Introduction of Defibrotide Sodium Anticoagulant into Peripheral Vein, Percutaneous Approach, New Technology Group 2 through FY2022 | Retired |
| XW03396 | Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6 | Valid |
| XW03398 | Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW0339A | Introduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW033A3 | Introduction of Bezlotoxumab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 3 through FY2022 | Retired |
| XW033A6 | Introduction of Cefiderocol Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW033A7 | Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW033B3 | Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3 | Valid |
| XW033B6 | Introduction of Omadacycline Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW033B7 | Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7 through FY2026 | Retired |
| XW033BA | Introduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW033C3 | Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3 through FY2021 | Retired |
| XW033C6 | Introduction of Eculizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW033C7 | Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW033CA | Introduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW033D6 | Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW033DA | Introduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW033E5 | Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5 | Valid |
| XW033E6 | Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW033F3 | Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3 | Valid |
| XW033F5 | Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5 | Valid |
| XW033F6 | Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 through FY2025 | Retired |
| XW033FA | Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW033FB | Introduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11 | Valid |